Search STRO
SUTRO BIOPHARMA, INC.
Nasdaq · CIK 1382101
Last close15.35
Daily change-0.62 (-3.88%)
10 Years gain-89.90%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
STRO · STANDARD
SIC 2836 · Biological Products, (No Diagnostic Substances) · Fiscal year end 1231
Fundamental
60.5Momentum
100.0Acceleration
100.0Confidence
76.0Annual Revenue10
Quarterly Revenue35
Annual CFO10
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth19.1 / 25
Quality16.4 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics10.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 260.1187 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Heavy share dilution · HIGHDiluted share count increased 98.1231%.
Key Metrics
Revenue Growth TTM51.32%OK
Revenue CAGR 3Y14.78%OK
Gross Margin100%OK
Operating Margin-113.85%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y-30.68%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y98.12%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $102.48M | $102.48M | -$158.37M | -$177.23M | n/a | 100% | -154.53% | n/a | n/a | 8.5M |
| 2025 FY Dec 31, 2024 | $62.04M | $62.04M | -$238.45M | -$191.54M | n/a | 100% | -384.34% | n/a | n/a | 7.74M |
| 2024 FY Dec 31, 2023 | $153.73M | $153.73M | -$89.28M | -$111.62M | n/a | 100% | -58.07% | n/a | n/a | 60.16M |
| 2024 FY Dec 31, 2022 | $67.77M | $67.77M | -$128.94M | $3.55M | n/a | 100% | -190.26% | n/a | -425.37% | 50.74M |
| 2023 FY Dec 31, 2021 | $61.88M | $61.88M | -$98.52M | -$81.68M | n/a | 100% | -159.22% | n/a | -105.88% | 46.12M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $97.80M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-345748, 0001193125-25-270036 |
| Revenue Growth TTM | 51.32% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-345748, 0001193125-25-270036 |
| Revenue CAGR 3Y | 14.78% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-119873 |
| Revenue CAGR 5Y | 19.12% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001193125-26-119873 |
| Gross Profit CAGR 3Y | 14.78% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001193125-26-119873 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-345748, 0001193125-25-270036 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001193125-26-345748, 0001193125-25-270036 |
| Operating Margin | -113.85% | Operating Income / Revenue | OK | 0001193125-26-345748, 0001193125-25-270036 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-345748 |
| Current Ratio | 3.32x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $5.90 | Revenue / Diluted Shares | OK | 0001193125-26-345748, 0001193125-25-270036 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001193125-26-119873 |